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Abstract
Aims/hypothesis Pancreatic islet transplantation (PIT) offers
a physiological treatment for type 1 diabetes, but the failure
of islet engraftment hinders its application. The female
hormone 17β-oestradiol (E2) favours islet survival and
stimulates angiogenesis, raising the possibility that E2 may
enhance islet engraftment following PIT.
Methods To explore this hypothesis, we used an insulin-
deficient model with xenotransplantation of a marginal dose
of human islets in nude mice rendered diabetic with streptozo-
tocin. This was followed by 4 weeks of treatment with vehicle,
E2, the non-feminising oestrogen 17α-oestradiol (17α-E2),
the oestrogen receptor (ER) α agonist propyl-pyrazole-triol
(PPT), the ERβ agonist diarylpropionitrile (DPN) or the G
protein-coupled oestrogen receptor (GPER) agonist G1.
Results Treatment with E2, 17α-E2, PPT, DPN or G1 acutely
improved blood glucose and eventually promoted islet en-
graftment, thus reversing diabetes. The effects of E2 were
retained in the presence of immunosuppression and persisted
after discontinuation of E2 treatment. E2 produced an acute
decrease in graft hypoxic damage and suppressed beta cell
apoptosis. E2 also acutely suppressed hyperglucagonaemia
without altering insulin secretion, leading to normalisation of
blood glucose.
Conclusions/interpretation During PIT, E2 synergistic
actions contribute to enhancing human islet-graft survival,
revascularisation and functional mass. This study identifies
E2 as a short-term treatment to improve PIT.
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GPER G protein-coupled oestrogen receptor
IEQ Islet equivalents
JDRF Juvenile Diabetes Research Foundation
PIT Pancreatic islet transplantation
PPT Propyl-pyrazole-triol
STZ Streptozotocin
TBARS Thiobarbituric acid reactive substances
Introduction
Replacing insulin-producing beta cells by human pancreatic
islet transplantation (PIT) offers a physiological therapeutic
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approach for type 1 diabetes. PIT benefits recipients in a
way that insulin therapy can never achieve [1–3]. Currently,
most immunosuppressed type 1 diabetic recipients of human
islets allotransplant [3, 4] can successfully attain insulin
independence and protection from hypoglycaemia at 1 year.
However, there are critical limitations to the widespread
application of PIT. First, procuring sufficient islet yield
requires several deceased human donors and novel strate-
gies are needed to achieve insulin independence with fewer
islets [4]. Evidence suggests that as little as 20% of the islets
within a pancreas are required to maintain euglycaemia [5].
Still, the islets of one or two pancreases are needed to
reverse diabetes following PIT, suggesting that a significant
portion of the transplanted islets are destroyed or become
non-functional. This early islet loss is believed to represent
up to 70% of the transplanted islet mass [6–8]. The trans-
planted islets are avascular, and islet revascularisation takes
2–3 weeks to complete. During that period, the islets are
vulnerable to hypoxic stress and may be destroyed before
revascularisation and engraftment occur [9, 10]. Thus, in the
immediate post-transplant period, apoptosis and failure of
vascular engraftment pose a challenging problem. We must
explore new therapeutic approaches promoting islet survival
and revascularisation to enhance islet engraftment.
Recently, the female hormone, 17β-oestradiol (E2) has
been shown to protect mouse and human islets from apo-
ptosis induced by multiple injuries and to stimulate insulin
biosynthesis via oestrogen receptors (ERs) present in beta
cells [11–18]. E2 also stimulates endometrial angiogenesis
and promotes endothelial cell recovery after injury [19–23].
Together, these findings raise the prospect that E2 may be
applied to improve islet functional mass and revascularisa-
tion during PIT. Here, we used an insulin-deficient mouse
model with xenotransplantation of a marginal dose of hu-
man islets to test the hypothesis that oestrogens improve
islet engraftment during PIT.
Methods
Animals and the induction of experimental diabetes Diabe-
tes was induced in 10-week-old male nude mice (C57BL/6;
Harlan Laboratories, Indianapolis, IN, USA) or male mice
null for Erα [24] by a single i.p. injection of 200 mg/kg
streptozotocin (STZ; Sigma Aldrich, St Louis, MO, USA).
Blood glucose was monitored with a One Touch Ultra
Glucose Monitor (LifeScan, Milpitas, CA, USA). Mice with
fed blood glucose exceeding 20.8 mmol/l were used as
recipients. All animal experiments were approved by North-
western University Animal Care and Use Committee.
Human islet transplantation and in vivo oestrogen treatment
Human islets were obtained through the Integrated Islet
Distribution Program and cultured for 48 h in phenol-red-
free CMRL-1066 medium (Sigma Aldrich) containing 10%
(vol./vol.) charcoal-stripped FBS (Gemini Bio, West Sacra-
mento, CA, USA). For in vivo treatment, E2, 17α-oestradiol
(17α-E2) and G1 (0.18 mg/pellet), propyl-pyrazole-triol
(PPT) and diarylpropionitrile (DPN) (3.6 mg/pellet) 60-
day-release pellets (Innovative Research of America, Sara-
sota, FL, USA) were implanted subcutaneously immediately
before islet transplantation. The dose of E2 was chosen to
obtain serum concentrations within physiological limits
(ranging from oestrus to pregnancy). The doses of 17α-E2
and G1, PPT and DPN were chosen according to the affinity
of each agonist for its ER to achieve similar activation of
ERs as caused by E2. A marginal dose of 1,000 islet equiv-
alents (IEQ) of human islets were transplanted under the
kidney capsule of recipient mice.
Immunosuppression Immunosuppression was achieved as
described in the Edmonton protocol, following adaptation
to the mouse [1, 25]. Sirolimus (rapamycin; LC Laborato-
ries, Woburn, MA, USA) was administered via i.p. injection
every other day at the dose of 0.1 mg/kg for 4 weeks,
starting from the day of islet transplantation. Tacrolimus
(FK506; Cayman, Ann Arbor, MI, USA) was administered
i.p. daily at 1 mg/kg, starting on the day of islet transplan-
tation. Control animals received daily vehicle injections.
Immunohistochemistry Kidneys bearing islet grafts were
fixed overnight in 4% (wt/vol) paraformaldehyde at 4°C.
The tissues were immersed in 30% (wt/vol) sucrose and
embedded in tissue-freezing medium (Tissue-Tek; Sakura
Finetek, Torrance, CA, USA). Sections, 5–10 μm, were
mounted on charged slides. For immunohistochemical stud-
ies, the following primary antibodies were used: guinea pig
anti-human insulin (1:1,000; Linco Research, Saint Charles,
MO, USA); rat anti-mouse CD31 (1:400; BD Biosciences,
San Jose, CA, USA); rabbit anti-mouse Ki67 (1:400; Novo-
castra, Newcastle Upon Tyne, UK); rat anti-mouse F4/80
(1:200; AbD Serotec, Raleigh, NC, USA); mouse anti-ERα
(1D5; 1:100; Zymed Laboratories, South San Francisco,
CA, USA); and goat anti-ERβ (Y-19; 1:100; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The secondary anti-
bodies were: Cy3-conjugated donkey anti-guinea pig; Cy3-
conjugated goat anti-rat; biotinylated goat anti-rat; FITC-
conjugated goat anti-rat; and FITC-conjugated donkey anti-
rabbit (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA). Biotinylated goat anti-rat was visualised
using the Vectastain Elite ABC kit (Vector Laboratories,
Burlingame, CA, USA). For staining with ERα and ERβ,
the Alexa 568 tyramide signal amplification kit (Molecular
Probes, Eugene, OR, USA) was used. For nuclear staining,
the sections were incubated with DAPI (Molecular Probes,
Eugene, OR, USA). Images were obtained with a Nikon
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Eclipse E400 microscope (Nikon Instruments, Melville,
New York, USA) or TissueGnostics High Throughput
Imaging System (TissueGnostics, Vienna, Austria).
Measurement of apoptosis using TUNEL assay Apoptotic
cells were detected by TUNEL assay using a fluorescein in
situ cell death detection kit (Roche, Indianapolis, IN, USA)
1 day after transplantation. Frozen tissue sections, 5 μm,
were fixed at room temperature for 1 h in 4% (vol./vol.) PFA
in PBS, pH7.4. Samples were washed in PBS for 30 min.
Following the manufacturer’s instructions, sections were
permeabilised, washed, labelled, incubated and analysed.
Sections were subsequently stained with guinea pig anti-
human insulin as a primary antibody (1:1,000) and Cy3-
conjugated donkey anti-guinea pig as a secondary antibody.
Images were obtained with a Nikon Eclipse E400 microscope.
Measurement of oxygenation in transplanted islet graft Islet
oxygenation was investigated in the transplants, 1 day post-
transplantation [26]. Pimonidazole hydrochloride (hpi
Hydroxyprobe-1; Omni Kit, Burlington, MA, USA)
(60 mg/kg) was injected i.p. Mice were killed 3 h later,
and their kidney containing the islet graft was processed
for immunohistochemistry. Rabbit anti-pimonidazole anti-
body (hpi Hydroxyprobe-1; Omni Kit) was used to visualise
pimonidazole hydrochloride accumulation in hypoxic cells
of the graft.
Morphometric analysis Kidneys bearing islet grafts were
sectioned in 10 μm thickness and four sections per tissue
were randomly chosen for morphometric analysis. Anti-
human-insulin and anti-mouse-CD31 antibodies were used
to visualise beta cells and blood vessels, respectively. Mor-
phometric analysis was conducted using the ImageJ 1.37v
(rsb.info.nih.gov/ij/) program. In islet transplants, the beta
cell area was calculated by dividing the insulin-positive area
by the graft area. Blood vessel density was calculated by
dividing the mouse-CD31-positive area by the graft area
[27]. The demarcation of an islet graft was considered to be
the parenchyma of the surrounding kidney as described [10].
Hormone and thiobarbituric acid reactive substances assays
Human insulin and mouse glucagon was measured in se-
rum by ELISA and RIA, respectively (Linco, St Charles,
MO, USA). Systemic oxidative stress was assessed by
measuring the concentration of thiobarbituric acid reactive
substances (TBARS) in plasma (Cayman) and kidney
homogenates (ZeptoMetrix, Franklin, MA, USA) [28].
Lectin infusion Biotinylated tomato lectin (Vector Labora-
tories) was injected into the tail vein (200 μg) and allowed
to circulate for 5 min before the mice were killed. The
kidneys bearing the islet grafts were removed and prepared
for histological study. Lectin staining was visualised using
the Vectastain Elite ABC kit (Vector Laboratories). Func-
tional blood vessel density was obtained by dividing the
lectin-positive area by the graft area.
Statistical analysis Data are presented as mean±SEM un-
less otherwise stated. For the rodent study, data were ana-
lysed by either the unpaired Student’s t test or one-way
ANOVA. A value of p<0.05 was considered statistically
significant.
Results
Oestrogens ameliorate diabetes We investigated the thera-
peutic action of oestrogens on islet transplantation out-
comes. We used male immunodeficient nude mice
rendered totally insulin deficient by injection of a single
high dose of STZ (200 mg/kg). In these mice, we performed
either sham transplantation or xenotransplantation of a mar-
ginal dose of human islets (1,000 IEQ) under the renal
capsule (PIT). This was followed by treatment with vehicle
or E2, leading to serum concentrations within the physio-
logical range (E2 levels: vehicle 68.49±25.5 pg/ml; E2
injection 321.93±77.15 pg/ml), the non-feminising E2 ste-
reoisomer 17α-E2 [29], the ERα-selective agonist PPT [30],
the ERβ-selective agonist DPN [31] and the G protein-
coupled oestrogen receptor (GPER) agonist G1 [32]. Fol-
lowing PIT or sham transplantation, blood glucose was
monitored for 3 weeks. PIT mice treated with vehicle
remained hyperglycaemic, but conversely, PIT mice treated
with E2, 17α-E2, PPT, DPN or G1 showed a dramatic
improvement in blood glucose (Fig. 1a–f) starting 1 day
after transplantation. In sham-operated diabetic mice, E2,
17α-E2, PPT, DPN and G1 treatment had no effect on blood
glucose (Fig. 1a–f) or body weight (electronic supplemen-
tary material [ESM] Fig. 1) compared with vehicle. This
finding demonstrated that the improvement in blood glucose
by ER agonists required the presence of transplanted human
islets. A similar protection of human PIT was observed in
female nude mice treated with E2 (ESM Fig. 2), demon-
strating that E2 protection is not sex specific. Thus, we
performed the rest of the study in male mice.
Oestrogens enhance islet engraftment At 4 weeks after PIT,
mice treated with E2, 17α-E2, PPT, DPN or G1 showed
protection of islet-graft beta cell mass (Fig. 2a, b) associated
with a rise in human serum insulin concentrations compared
with vehicle-treated PIT mice (Fig. 2c). Insulin response to
i.p. arginine was also increased in the E2- compared with the
vehicle-treated mice (Fig. 2d, e). Additionally, the endoge-
nous pancreatic beta cell mass of STZ-treated PIT recipient
mice was efficiently reduced and unaffected by ER agonist
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treatments (ESM Fig. 3). Thus, activation of ERα, ERβ and
GPER with oestrogens preserves functional islet mass and
reverses diabetes after PIT.
We next quantified the endothelial cell area in islet grafts
using the mouse endothelial cell marker CD31. At 4 weeks
after PIT, mice treated with E2, 17α-E2, PPT or DPN
showed an improvement in islet revascularisation compared
with vehicle-treated mice (Fig. 2f, g). Conversely, the mice
treated with G1 did not show any improvement compared
with controls (Fig. 2f, g). To determine the functionality of
the E2-induced reconstructed islet vasculature network, we
applied in vivo staining for lectin—a commonly used mark-
er of vessel functionality [33]—to a group of mice treated
with vehicle or E2. We detected increased lectin staining in
E2-treated mice compared with vehicle-treated mice
(Fig. 2h, i), demonstrating that E2 increased functional
vessel density in the transplanted islets. While the contribu-
tion of endothelial cells from freshly isolated donor islets to
the formation of functional vessels within islet grafts has
been demonstrated [33, 34], cultured islets lose most of their
endothelial cell populations within 3 days of culture [34].
We thus examined whether E2 treatment could preserve the
intra-islet endothelial cell population in freshly isolated
mouse islets. Consistent with a previous report [34], we
observed that the islet endothelial cell number decreased
within 1 day of culture and totally disappeared after 3 days.
However, we observed no beneficial effect of E2 treatment
on the maintenance of intra-islet endothelial cell population
(ESM Fig. 4). As E2 favours islet survival, we tested wheth-
er in vitro E2 treatment of human islets prior to PIT could
improve PIT outcome using the same model system. We
observed that E2 treatment of cultured human islets prior to
PIT had no significant effect on subsequent glycaemic con-
trol either alone or in association with in vivo E2 treatment
(ESM Fig. 5).
Improvement of islet engraftment persists in the presence
of immunosuppression and after discontinuation of E2
treatment The Edmonton protocol has facilitated human
islet transplantation by using non-steroidal immunosuppres-
sive treatment such as sirolimus (rapamycin) and tacrolimus
(FK-506) [1, 3]. However, these regimens undermine
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Fig. 1 Oestrogens ameliorate
diabetes after PIT. Effect of (a)
E2, (b) 17α-E2, (c) PPT, (d)
DPN and (e) G1 on blood glu-
cose after PIT. (f) Blood glu-
cose AUC was calculated from
(a–e). Values represent the
mean±SEM, n04–18/group.
*p<0.05, **p<0.01. AS, after
STZ; BS, before STZ; V,
vehicle
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angiogenesis and represent a significant obstacle to islet
engraftment [35, 36]. To determine the persistence of E2
improvement of islet engraftment after PIT in the presence
of immunosuppression, we treated a group of mice with
sirolimus and tacrolimus for 4 weeks in the presence of
vehicle or E2. The treatments did not alter E2-induced
improvement of glycaemic control and islet revascularisa-
tion (Fig. 3a, b), demonstrating that E2 improves PIT in the
presence of immunosuppression. As chronic E2 treatment
following islet transplantation is not suitable in the clinical
setting, we sought to determine whether glycaemic control
could be sustained after E2 discontinuation. We followed a
group of PIT mice for 112 days, during which time we
maintained the E2 treatment for the first 60 days. Our results
show that E2 efficacy on PIT outcome, assessed by normal-
isation of blood glucose, lasted for 50 days after E2 discon-
tinuation (Fig. 3c). These findings suggest that transient E2
treatment has induced a permanent improvement in func-
tional islet mass and engraftment.
E2 acutely improves islet-graft hypoxia The acute correc-
tion of hyperglycaemia observed 1 day after transplantation
(Fig. 1)—a time when revascularisation has not yet taken
place—suggested that oestrogens had acutely improved islet
survival and/or function independently from the graft revas-
cularisation. Because the process of islet transplantation
elicits an acute inflammatory response, we first looked at
whether E2 had acutely suppressed graft inflammation. We
observed no difference between the E2- and vehicle-treated
groups in graft macrophage infiltration (ESM Fig. 6). E2
improves splanchnic macro- and microcirculation during
haemorrhagic shock [37]. A similar improvement in renal
cortex microcirculation would improve islet-graft oxygena-
tion, thus improving survival and function at this early stage
when islets are not revascularised. To explore this possibil-
ity, we quantified graft hypoxia using pimonidazole [26] at
1 day after PIT. We observed a marked decrease in the
hypoxic area in E2-treated grafts (Fig. 4a). Hyperglycaemia



































































































































































Fig. 2 Oestrogens improve islet engraftment after PIT. (a) Represen-
tative sections showing immunofluorescence staining for insulin-
positive cells in islet grafts. (b) Quantification of graft beta cell area
(insulin-positive area/total graft area). (c) Ratio of random-fed insulin
(pmol/l)/glucose (mmol/l) was used as an index of insulin production.
(d) Insulin response to L-arginine (ASIS) (black, vehicle; white, E2)
following i.p. L-arginine injection (3 g/kg). (e) AUC for ASIS from (d).
(f) Representative sections of mouse CD31 immunofluorescence stain-
ing in islet grafts. (g) Quantification of graft blood vessel density
(CD31-positive area/graft area). (h) Representative sections showing
lectin staining in islet grafts. (i) Quantification of graft functional blood
vessel density (lectin-positive area/graft area). In (a) and (f) the cell
nuclei were stained with DAPI (blue). Values represent the mean±
SEM, n03–9/group. *p<0.05. Scale bars, 100 μm. V, vehicle
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and lipid peroxidation that trigger islet apoptosis. To measure
oxidative stress, we quantified lipid peroxidation in serum and
kidney tissue adjacent to the graft using the TBARS method
[28]. We observed decreased serum and kidney TBARS con-
centration in E2-treated mice, demonstrating that E2 treatment
has improved hypoxic stress in these mice (Fig. 4b, c).
E2 acutely suppresses graft beta cell apoptosis We next
studied graft beta cell turnover and function in the early
post-transplant period. We observed that E2 treatment acute-
ly suppressed apoptosis (day 1 after PIT; Fig. 5a), without
an effect on beta cell proliferation (ESM Fig. 7). This was
associated with a greater beta cell graft area (day 3 after PIT;
Fig. 5b), suggesting a retained beta cell mass. E2 treatment
dramatically improved i.p. glucose tolerance in PIT mice
(Fig. 5c) but, surprisingly, despite the retained beta cell area,
E2 acute suppression of blood glucose was not associatedwith
increased glucose-stimulated insulin secretion (Fig. 5d) and
random-fed insulin concentrations were reduced (Fig. 5e).
PPT acutely suppresses blood glucose in the absence of
ERα in the islet graft As E2 suppression of blood glucose
was independent from an enhanced insulin secretion from
the islet graft, we asked whether this effect required direct
activation of ER in the islet graft or ER activation in the
recipient tissue (leading to increased insulin sensitivity). To
address this issue, we used ERα as a paradigm of E2 actions
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aFig. 3 Improvement of PIT
persists in the presence of
immunosuppression and
after discontinuation of E2
treatment. (a) Line graph
showing the effect of E2 on
blood glucose in the presence of
immunosuppressive treatment
(black circles, PIT+V; white
circles, PIT+E2; black triangles,
PIT+E2+ immunosuppressant),
and bar chart showing blood
glucose AUC as calculated
from the graph. (b)
Quantification of graft blood
vessel density (CD31-positive
area/graft area) in mice from
(a). (c) Blood glucose was
measured in vehicle-treated
(black circles) and E2-treated
(white circles) mice on the
indicated days. Values represent
the mean±SEM, n07–9/group.
*p<0.05. AS, after STZ; BS,



























































Fig. 4 E2 acutely improves islet-graft hypoxia. (a) Representative
pictures of pimonidazole staining (green) in the islet grafts, 1 day after
PIT, and bar chart showing pimonidazole-positive area in the graft. In
the images, red fluorescence has been used for insulin. The cell nuclei
were stained with DAPI (blue). Lipid peroxidation was determined in
(b) plasma and in (c) islet-bearing kidney homogenates, 1 day after
PIT, by TBARS assay. Values represent the mean±SEM, n03–8/
group. *p<0.05. Scale bars, 50 μm. V, vehicle
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Fig. 6 E2 acutely suppresses
blood glucose via ERα
activation outside the islet graft.
(a) Line graph showing the
effect of PPT on blood glucose
after transplantation of WT and
Erα−/− mouse islets in WT
recipient mice and bar chart
showing corresponding glucose
AUC. (b) Line graph showing
the effect of PPT on blood
glucose after transplantation of
WT mouse islet in Erα−/−
recipient mice (blue, vehicle;
green, PPT), and bar chart
showing the corresponding
blood glucose AUC. Values
represent the mean±SEM,
n03–14/group. *p<0.05.
AS, after STZ; BS, before STZ;
V, vehicle
c
















































































































































aFig. 5 E2 treatment acutely




insulin-positive (red) cells in islet
grafts, 1 day after PIT. Arrows
show TUNEL-positive beta cells.
Bar charts show quantification of
TUNEL-positive/beta cells (insu-
lin-positive) area in the graft. Scale
bar, 25 μm. (b) Representative
sections showing immunofluores-
cence staining for insulin-positive
(red) cells in islet grafts. Bar charts
showing the percentage of insulin-
positive area in graft. Scale bar
100 μm. (c) Line graph showing
results of i.p. glucose tolerance test
(2 mg/kg body weight; black
circles, vehicle; white circles, E2),
and bar chart with corresponding
AUC for glucose. (d) Insulin se-
cretion after i.p.GTT (black circles,
vehicle; white circles, E2). (e)
Plasma human insulin levels. In (a)
and (b) the cell nuclei were stained
with DAPI (blue). In (b), (c), (d)
and (e) measurements were made
on day 3 after PIT.Values represent
the mean±SEM, n05–11/group.
*p<0.05, **p<0.01. V, vehicle
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first performed an allotransplantation of a marginal dose of
islets (150) isolated from donor littermate wild-type (WT) or
Erα−/− mice under the kidney capsule of recipient WT mice.
These recipient mice were treated with vehicle or the ERα-
selective agonist PPT. As expected, WT mice transplanted
with WT or Erα−/− islets and treated with vehicle remained
hyperglycaemic. However, PPT treatment led to a similar
early decrease in blood glucose in WT mice transplanted with
WT or Erα−/− islets, demonstrating that PPT improves PIT in
the absence of islet ERα (Fig. 6a). Next, we performed an
allotransplantation of a marginal dose ofWT islets in recipient
Erα−/− mice followed by treatment with vehicle or PPT.
Vehicle- and PPT-treated mice showed a similar and minor
blood-glucose-lowering effect due to the transplantation of
WT islets in Erα−/− mice. However, PPT treatment did not
produce a stronger hypoglycaemic effect than vehicle in these
ERα-deficient mice. Together, these data demonstrate the
requirement of ERα activation in the recipient mouse tissues
to acutely suppress blood glucose (Fig. 6b).
E2 acutely suppresses glucagon production That treatment
with the ERα agonist PPT produced an acute decrease in
blood glucose in the absence of ERα in the islet graft and
without an increase in insulin secretion suggests that PPT
acts on the host alpha cells to suppress glucagon secretion.
Indeed, unsuppressed hyperglucagonaemia plays a major
role in hyperglycaemia in all forms of insulin-deficient
diabetes [38, 39]. To address this issue, we looked at the
effect of E2 treatment on serum glucagon in the early
transplant period. First, we observed that ERα and ERβ
were present in alpha cells from mice and human islets
(Fig. 7a–d). In glucagon-secreting INR1G9 cells and
αTC6 cells, the 67 kd-long isoform of ERα was produced
at a level similar to that in insulin-secreting MIN-6 cells
(ESM Fig. 8). In addition, we observed that 1 day after PIT,
E2 treatment was associated with a dramatic suppression of
serum glucagon compared with vehicle-treated mice in
random-fed state (−65%, Fig. 7e), thus providing an expla-
nation for the simultaneous decrease in glucose (Fig. 1a) and
insulin levels (Fig. 5e) associated with E2 treatment.
Discussion
The present study shows that E2, used at physiological
concentrations, improves islet engraftment in a sex-non-
specific manner in an insulin-deficient nude mouse model
transplanted with a marginal dose of human islets and in the
absence of allorejection or autoimmunity recurrence. Sever-
al non-exclusive mechanisms could be implicated.
Suppression of hyperglucagonaemia The acute correction
of hyperglycaemia and improvement of glucose tolerance
observed 1 day after transplantation and following E2 treat-
ment occur without an increase in graft insulin secretion. In
fact, E2 treatment produces a decrease in fed serum insulin
concentrations, suggesting that E2 has improved insulin
sensitivity. Indeed, the E2 hypoglycaemic action occurs in
the face of better suppression of serum hyperglucagonae-
mia. This observation suggests that the E2-mediated acute
suppression of blood glucose is independent of an improve-
ment in beta cell function; rather, it is dependent on gluca-






























Fig. 7 E2 acutely suppresses hyperglucagonaemia. Representative
pictures of islets showing co-localisation of (a) mouse ERα, (b) human
ERα, (c) mouse ERβ, and (d) human ERβ (green) with alpha cells
stained with glucagon (red). In (a) and (c), the cell nuclei were stained
with DAPI (blue). (e) Plasma glucagon levels at day 1 after PIT. Values
represent the mean±SEM, n03–5/group. **p<0.01. Scale bar, 25 μm.
h, human; m, mouse; V, vehicle
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have suppressed hyperglucagonaemia and lower insulin
concentrations, as a decrease in hyperglucagonaemia
improves glucagon-induced hepatic insulin resistance. This
observation is also consistent with the ‘glucagonocentric’
vision of diabetes pathophysiology in which glucagon ex-
cess, rather than insulin deficiency, is the sine qua non of
hyperglycaemia in all forms of diabetes, at least in rodents
[40]. Indeed, total insulin deficiency by beta cell destruction
in glucagon-receptor-null mice, which are unresponsive to
glucagon, does not cause diabetic abnormalities [41]. We
observe that ERα and ERβ are produced in mouse and
human alpha cells, further indicating that alpha cells are
direct targets of E2 actions. In addition, our experiments
suggest that ERα needs to be activated in alpha cells of the
host pancreas as the hypoglycaemic effect of an ERα-
selective agonist is lost when islets from WT mice are
transplanted in Erα null mice (lacking ERα in alpha cells).
Accordingly, the ERα agonist can still acutely suppress
blood glucose and permanently improve diabetes when
ERα-deficient islets are transplanted in WT mice. This
demonstrates that ERα action in graft alpha cells is not
necessary to suppress blood glucose. Recently, leptin has
been shown to suppress glucagon and correct diabetes in
mice, in the absence of insulin [42]. Our results suggest that
E2 requires the presence of insulin—or at least functional
beta cells—to suppress glucagon as ER agonists have no
hypoglycaemic effect in diabetic mice in the absence of
transplanted islets. This observation is consistent with the
concept that insulin suppresses glucagon secretion from
alpha cells via paracrine mechanisms [43] and that insulin
signalling in alpha cells is required for this process [44].
Thus, in the alpha cells of diabetic mice E2 may act as an
insulin sensitiser in suppressing glucagon production. Ad-
ditional studies in mice lacking ERs in alpha cells are
needed to address this issue.
Protection of functional beta cell mass Oestrogens have
acutely improved islet survival following transplantation,
as demonstrated by E2-mediated acute suppression of graft
apoptotic beta cells. This is the first evidence that E2, used
at therapeutic doses, protects human islets from apoptosis in
an in vivo diabetic environment. We and others have shown
that E2 promotes islet survival in conditions of oxidative
stress and pro-inflammatory cytokine injury in culture and
in vivo [11–13, 17]. Higher islet functionality and decreased
apoptosis are also observed after transplantation of rat islets
recovered from E2-treated brain-dead donors [45]. This anti-
apoptotic protection probably accounts for the early reten-
tion of graft beta cell mass, which persists after 3 weeks of
ER agonist treatment. In addition, we believe that E2 anti-
apoptotic protection is also mediated via activation of ERs
in recipient endothelial cells. E2 dilates the mesenteric ar-
teries and increases mesenteric blood flow [46, 47]. E2 also
improves splanchnic circulation during haemorrhagic shock,
which increases oxygenation [37]. We observed that E2
acutely and dramatically improved islet-graft hypoxia,
which is associated with decreased systemic and kidney





















Fig. 8 Schematic representation
of the proposed mechanisms of
E2 improvement of islet
engraftment. E2 exhibits acute
actions in recipient endothelial
cells, decreasing islet-graft hyp-
oxic stress, that synergise with
E2 acute action in graft beta cells
to prevent apoptosis. In addition,
E2 exhibits acute actions in re-
cipient alpha cells suppressing
hyperglucagonaemia and hyper-
glycaemia. These acute actions
help retain the initial beta cell
mass. E2 also exhibits late
actions on graft endothelial cells
to improve revascularisation.
These acute and late E2 actions
concur to promote islet engraft-
ment and maintenance of func-
tional beta cell mass
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probably instrumental in E2 acute anti-apoptotic protection
as, following PIT, hypoxic stress is a critical factor in the
early loss of islet mass [8–10]. Initially, E2-treated graft beta
cells are non-functional and show no insulin-secretory re-
sponse to the glucose challenge, probably as a result of
hyperglycaemia-induced glucose desensitisation and/or lack
of islet vascularisation. However, following 3 weeks of
normoglycaemia, PIT mice treated with ER agonists show
a restoration of beta cell function. Thus, E2 acute normal-
isation of blood glucose, via suppression of hyperglucago-
naemia, has favoured the subsequent restoration of beta cell
function following correction of glucose desensitisation.
Action on recipient endothelial cells Apart from E2-
mediated acute improvement of islet-graft oxygenation, the
likely action of oestrogens involves the enhancement of islet
revascularisation through action on recipient endothelial
cells, as E2 is a potent angiogenic factor in the endometrium
and following vascular injury [22, 23]. Accordingly, E2
increases the functional blood vessel density of the human
islet graft. More importantly, immunosuppression with siroli-
mus and tacrolimus typically inhibits islet revascularisation
and engraftment. Yet E2 stimulation of revascularisation per-
sists in the presence of this immunosuppression regimen.
Furthermore, after discontinuation of E2 treatment the correc-
tion of diabetes endures, demonstrating that E2 has induced a
stable engraftment. E2 treatment promotes revascularisation
of the transplanted human islets through ERs on the endothe-
lial cell from the recipient kidney cortex and without the
participation of endothelial cells from the human graft, as
these cells had disappeared at the time of transplantation.
However, G1, which exhibits potent anti-apoptotic action in
human islets [13], improves PIT outcome without enhancing
graft revascularisation, suggesting that the acute hypoglycae-
mic and anti-apoptotic effects of oestrogens are more impor-
tant to the engraftment process than the moderate increase in
revascularisation.
Thus, the synergistic actions of E2 on ERs in recipient
alpha cells, endothelial cells and graft beta cells leading,
respectively, to the suppression of hyperglucagonaemia and
hyperglycaemia, the protection from islet-graft hypoxia,
oxidative stress and apoptosis and ultimately to revascular-
isation of the graft, have concurred to promote islet engraft-
ment and maintenance of beta cell functional mass. A
summary of the proposed mechanisms of E2 action is shown
in Fig. 8.
Our findings have direct therapeutic implications for PIT
in type 1 diabetes. Although long-term E2 treatment follow-
ing PIT is not suitable because of the risk of cancer, con-
versely, transient E2 treatment represents a safe and
immediately available alternative to improve PIT in women.
Indeed, fertile women with type 1 diabetes show E2 defi-
ciency compared with healthy women [48]. Therefore,
women with type 1 diabetes undergoing islet transplantation
have lost their endogenous E2 protection and could benefit
from short-term oestrogen supplementation using therapeu-
tic doses. Furthermore, 17α-E2, which is endogenous in
humans, has few of the biological effects associated with
the female hormone activity and may be a candidate for sex-
neutral therapy in PIT.
In conclusion, E2 enhances islet engraftment after PIT.
As oestrogens are approved by the Food and Drug Admin-
istration, further testing in women with the addition of
oestrogens to the Edmonton protocol should be considered.
This could provide an immediate therapeutic alternative to
improve PIT and achieve insulin independence with fewer
islets, long before other surrogate islet beta cell sources or
beta cell regeneration therapy can be developed.
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